Evaluation of the efficacy of radiation-modifying compounds using γH2AX as a molecular marker of DNA double-strand breaks

Genome Integrity

Volumn 2, Issue , 2011, Pages

  Mah, Li Jeen ^a,b   Orlowski, Christian ^a,b   Ververis, Katherine ^a,b   Vasireddy, Raja S ^a,b   El Osta, Assam ^a,c   Karagiannis, Tom C ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; ACETYLCYSTEINE; AMIFOSTINE; BENZIMIDAZOLE DERIVATIVE; BUTYRIC ACID; CAPTOPRIL; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GAMMA HISTONE H2AX; HISTONE H2AX; MESNA; MOLECULAR MARKER; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITRIC OXIDE; NITROIMIDAZOLE DERIVATIVE; RADIOSENSITIZING AGENT; TEMPOL; TIRAPAZAMINE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CELL PROLIFERATION; CELL PROTECTION; CUTANEOUS T CELL LYMPHOMA; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; HEAD AND NECK CANCER; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; INTRACELLULAR SIGNALING; IONIZING RADIATION; MALIGNANT NEOPLASTIC DISEASE; NEPHROTOXICITY; NONHUMAN; ORAL MUCOSITIS; OVARY CANCER; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; RADIATION MONITORING; RADIATION PROTECTION; RADIOSENSITIZATION; REVIEW; RISK BENEFIT ANALYSIS; THERAPY EFFECT; XEROSTOMIA;

EID: 84861010003     PISSN: None     EISSN: 20419414     Source Type: Journal    
DOI: 10.1186/2041-9414-2-3     Document Type: Review

References (162)

1. Little JB. Genomic instability and radiation. J Radiol Prot 2003, 23:173-181. 10.1088/0952-4746/23/2/304, 12875549.
2. Sedelnikova OA, Pilch DR, Redon C, Bonner WM. Histone H2AX in DNA damage and repair. Cancer Biology & Therapy 2003, 2:233-235.
3. Cadet J, Delatour T, Douki T, Gasparutto D, Pouget J, Ravanat J, Sauvaigo S. Hydroxyl radicals and DNA base damage. Mutat Res 1999, 424:9-21.
4. Pouget JP, Mather SJ. General aspects of the cellular response to low- and high-LET radiation. Eur J Nucl Med 2001, 28:541-561. 10.1007/s002590100484, 11357507.
5. Karagiannis TC, El-Osta A. Double-strand breaks: signaling pathways and repair mechanisms. Cell Mol Life Sci 2004, 61:2137-2147. 10.1007/s00018-004-4174-0, 15338043.
6. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001, 27:247. 10.1038/85798, 11242102.
7. Pastink A, Lohman PHM. Repair and consequences of double-strand breaks in DNA. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1999, 428:141-156.
8. Rich T, Allen RL, Wyllie AH. Defying death after DNA damage. Nature 2000, 407:777-783. 10.1038/35037717, 11048728.
9. Stucki M, Clapperton JA, Mohammad D, Yaffe MB, Smerdon SJ, Jackson SP. MDC1 Directly Binds Phosphorylated Histone H2AX to Regulate Cellular Responses to DNA Double-Strand Breaks. Cell 2005, 123:1213-1226. 10.1016/j.cell.2005.09.038, 16377563.
10. Sonoda E, Hochegger H, Saberi A, Taniguchi Y, Takeda S. Differential usage of non-homologous end-joining and homologous recombination in double strand break repair. DNA Repair 2006, 5:1021-1029. 10.1016/j.dnarep.2006.05.022, 16807135.
11. Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res 2008, 18:134-147. 10.1038/cr.2007.111, 18157161.
12. Fernandez-Capetillo O, Chen HT, Celeste A, Ward I, Romanienko PJ, Morales JC, Naka K, Xia Z, Camerini-Otero RD, Motoyama N, et al. DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Nat Cell Biol 2002, 4:993. 10.1038/ncb884, 12447390.
13. Lees-Miller SP, Sakaguchi K, Ullrich SJ, Appella E, Anderson CW. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol Cell Biol 1992, 12:5041-5049. 360437, 1406679.
14. Karlsson K, Stenerlöw B. Focus formation of DNA repair proteins in normal and repair-deficient cells irradiated with high-LET ions. Radiat Res 2004, 161:517-527. 10.1667/RR3171, 15161372.
15. Leatherbarrow EL, Harper JV, Cucinotta FA, O'Neill P. Induction and quantification of g-H2AX foci following low and high LET-irradiation. Int J Radiat Biol 2006, 82:111-118. 10.1080/09553000600599783, 16546909.
16. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998, 273:5858-5868. 10.1074/jbc.273.10.5858, 9488723.
17. Rogakou EP, Boon C, Redon C, Bonner WM. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 1999, 146:905-916. 10.1083/jcb.146.5.905, 2169482, 10477747.
18. Sedelnikova OA, Rogakou EP, Panyutin IG, Bonner WM. Quantitative detection of (125) IdU-induced DNA double-strand breaks with gamma-H2AX antibody. Radiat Res 2002, 158:486-492. 10.1667/0033-7587(2002)158[0486:QDOIID]2.0.CO;2, 12236816.
19. Rothkamm K, Lobrich M. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses. Proc Natl Acad Sci USA 2003, 100:5057-5062. 10.1073/pnas.0830918100, 154297, 12679524.
20. Chen HT, Bhandoola A, Difilippantonio MJ, Zhu J, Brown MJ, Tai X, Rogakou EP, Brotz TM, Bonner WM, Ried T, Nussenzweig A. Response to RAG-Mediated V(D)J Cleavage by NBS1 and {gamma}-H2AX. Science 2000, 290:1962-1964. 10.1126/science.290.5498.1962, 11110662.
21. Markova E, Schultz N, Belyaev IY. Kinetics and dose-response of residual 53BP1/gamma-H2AX foci: Co-localization, relationship with DSB repair and clonogenic survival. Int J Radiat Biol 2007, 83:319-329. 10.1080/09553000601170469, 17457757.
22. Nakamura AJ, Redon CE, Sedelnikova OA. Where did they come from? The origin of endogenous gamma-H2AX foci in tumor cells. Cell Cycle 2009, 8:2324. 10.4161/cc.8.15.9311, 19633409.
23. Yu T, MacPhail SH, Banath JP, Klokov D, Olive PL. Endogenous expression of phosphorylated histone H2AX in tumors in relation to DNA double-strand breaks and genomic instability. DNA Repair (Amst) 2006, 5:935-946. 10.1016/j.dnarep.2006.05.040, 16814620.
24. Banath JP, Banuelos CA, Klokov D, MacPhail SM, Lansdorp PM, Olive PL. Explanation for excessive DNA single-strand breaks and endogenous repair foci in pluripotent mouse embryonic stem cells. Exp Cell Res 2009, 315:1505-1520. 10.1016/j.yexcr.2008.12.007, 19154734.
25. Anderson JA, Harper JV, Cucinotta FA, O'Neill P. Participation of DNA-PKcs in DSB repair after exposure to high- and low-LET radiation. Radiat Res 2010, 174:195-205. 10.1667/RR2071.1, 20681786.
26. Schmid TE, Dollinger G, Beisker W, Hable V, Greubel C, Auer S, Mittag A, Tarnok A, Friedl AA, Molls M, Roper B. Differences in the kinetics of gamma-H2AX fluorescence decay after exposure to low and high LET radiation. Int J Radiat Biol 2010, 86:682-691. 10.3109/09553001003734543, 20569192.
27. Roig AI, Hight SK, Minna JD, Shay JW, Rusek A, Story MD. DNA damage intensity in fibroblasts in a 3-dimensional collagen matrix correlates with the Bragg curve energy distribution of a high LET particle. Int J Radiat Biol 2010, 86:194-204. 10.3109/09553000903418603, 20201648.
28. Takahashi A, Yamakawa N, Kirita T, Omori K, Ishioka N, Furusawa Y, Mori E, Ohnishi K, Ohnishi T. DNA damage recognition proteins localize along heavy ion induced tracks in the cell nucleus. J Radiat Res (Tokyo) 2008, 49:645-652. 10.1269/jrr.08007, 18987440.
29. Leatherbarrow EL, Harper JV, Cucinotta FA, O'Neill P. Induction and quantification of gamma-H2AX foci following low and high LET-irradiation. Int J Radiat Biol 2006, 82:111-118. 10.1080/09553000600599783, 16546909.
30. Desai N, Davis E, O'Neill P, Durante M, Cucinotta FA, Wu H. Immunofluorescence detection of clustered gamma-H2AX foci induced by HZE-particle radiation. Radiat Res 2005, 164:518-522. 10.1667/RR3431.1, 16187760.
31. Feuerhahn S, Egly JM. Tools to study DNA repair: what's in the box?. Trends Genet 2008, 24:467-474. 10.1016/j.tig.2008.07.003, 18675488.
32. Redon CE, Dickey JS, Bonner WM, Sedelnikova OA. [gamma]-H2AX as a biomarker of DNA damage induced by ionizing radiation in human peripheral blood lymphocytes and artificial skin. Advances in Space Research 2009, 43:1171-1178. 10.1016/j.asr.2008.10.011, 2735274, 20046946.
33. Sedelnikova OA, Bonner WM. gamma H2AX in cancer cells: A potential biomarker for cancer diagnostics, prediction and recurrence. Cell Cycle 2006, 5:2909-2913. 10.4161/cc.5.24.3569, 17172873.
34. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870. 10.1038/nature03482, 15829956.
35. Gorgoulis VG, Vassiliou L-VF, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, DiTullio RA, Kastrinakis NG, Levy B, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913. 10.1038/nature03485, 15829965.
36. Olive PL, Banath JP. Phosphorylation of histone H2AX as a measure of radiosensitivity. 2004, 331-335.
37. Rothkamm K, Kruger I, Thompson LH, Lobrich M. Pathways of DNA Double-Strand Break Repair during the Mammalian Cell Cycle. Mol Cell Biol 2003, 23:5706-5715. 10.1128/MCB.23.16.5706-5715.2003, 166351, 12897142.
38. Karagiannis TC, Harikrishnan KN, El-Osta A. Disparity of histone deacetylase inhibition on repair of radiation-induced DNA damage on euchromatin and constitutive heterochromatin compartments. Oncogene 2007, 26:3963-3971. 10.1038/sj.onc.1210174, 17213813.
39. Goodarzi AA, Noon AT, Deckbar D, Ziv Y, Shiloh Y, Löbrich M, Jeggo PA. ATM Signaling Facilitates Repair of DNA Double-Strand Breaks Associated with Heterochromatin. Mol Cell 2008, 31:167-177. 10.1016/j.molcel.2008.05.017, 18657500.
40. Cowell IG. gammaH2AX foci form preferentially in euchromatin after ionising-radiation. PLoS ONE 2007, 2:e1057. 10.1371/journal.pone.0001057, 2020439, 17957241.
41. Vasireddy RS, Karagiannis TC, El-Osta A. gamma-radiation-induced gammaH2AX formation occurs preferentially in actively transcribing euchromatic loci. Cell Mol Life Sci 2010, 67:291-294. 10.1007/s00018-009-0181-5, 19859659.
42. Kim JA, Kruhlak M, Dotiwala F, Nussenzweig A, Haber JE. Heterochromatin is refractory to gammaH2AX modification in yeast and mammals. J Cell Biol 2007, 178:209-218. 10.1083/jcb.200612031, 2064441, 17635934.
43. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, Pommier Y. Gamma H2AX and cancer. Nature Reviews Cancer 2008, 8:957-967. 10.1038/nrc2523, 19005492.
44. Kouzarides T. Chromatin Modifications and Their Function. Cell 2007, 128:693-705. 10.1016/j.cell.2007.02.005, 17320507.
45. Taddei A, Maison C, Roche D, Almouzni G. Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat Cell Biol 2001, 3:114-120. 10.1038/35055010, 11175742.
46. Kruhlak MJ, Celeste A, Dellaire G, Fernandez-Capetillo O, Muller WG, McNally JG, Bazett-Jones DP, Nussenzweig A. Changes in chromatin structure and mobility in living cells at sites of DNA double-strand breaks. J Cell Biol 2006, 172:823-834. 10.1083/jcb.200510015, 2063727, 16520385.
47. Dunne-Daly C. Principles of radiotherapy and radiobiology. Semin Oncol Nurs 1999, 15:250-259. 10.1016/S0749-2081(99)80054-0, 10588029.
48. Bacq Z, Dechamps G, Fischer P, Herve A, Le Bihan H, Lecomte J, Pirotte M, Rayet P. Protection against x-rays and therapy of radiation sickness with beta-mercaptoethylamine. Science 1953, 117:633-636. 10.1126/science.117.3049.633, 13056641.
49. Patt H, Tyree E, Straube R, Smith D. Cysteine Protection against X Irradiation. Science 1949, 110:213-214. 10.1126/science.110.2852.213, 17811258.
50. Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: The First Selective-Target and Broad-Spectrum Radioprotector. Oncologist 2007, 12:738-747. 10.1634/theoncologist.12-6-738, 17602063.
51. Marcu LG. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy. European Journal of Cancer Care 2009, 18:116-123. 10.1111/j.1365-2354.2008.01032.x, 19267726.
52. Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, Gradishar WJ, Green DM, Langdon RJ, Mitchell RB, et al. American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants. J Clin Oncol 1999, 17:3333-3355.
53. Koukourakis M. Amifostine: is there evidence of tumor protection?. Semin Oncol 2003, 30:18-30. 10.1053/j.seminoncol.2003.11.014, 14727237.
54. Sasse A, Clark L, Sasse E, Clark O. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int J Radiat Oncol Biol Phys 2006, 64:784-791. 10.1016/j.ijrobp.2005.06.023, 16198504.
55. Yuhas J, Spellman J, Culo F. The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 1980, 3:211-216.
56. Calabro-Jones P, Fahey R, Smoluk G, Ward J. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol Relat Stud Phys Chem Med 1985, 47:23-27. 10.1080/09553008514550041, 2982751.
57. Yuhas JM. Active versus Passive Absorption Kinetics as the Basis for Selective Protection of Normal Tissues by S-2-(3-Aminopropylamino)-ethylphosphorothioic Acid. Cancer Res 1980, 40:1519-1524.
58. Purdie J, Inhaber E, Schneider H, Labelle J. Interaction of cultured mammalian cells with WR-2721 and its thiol, WR-1065: implications for mechanisms of radioprotection. Int J Radiat Biol Relat Stud Phys Chem Med 1983, 43:517-527. 10.1080/09553008314550611, 6303973.
59. Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002, 52:739-747. 10.1016/S0360-3016(01)02683-9, 11849797.
60. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W, Sauer R. Phase III Randomized Trial of Amifostine as a Radioprotector in Head and Neck Cancer. J Clin Oncol 2000, 18:3339-3345.
61. Kataoka Y, Murley JS, Baker KL, Grdina DJ. Relationship between phosphorylated histone H2AX formation and cell survival in human microvascular endothelial cells (HMEC) as a function of ionizing radiation exposure in the presence or absence of thiol-containing drugs. Radiat Res 2007, 168:106-114. 10.1667/RR0975.1, 1958995, 17723002.
62. Bennett H, Swartz H, Brown R, Koenig S. Modification of relaxation of lipid protons by molecular oxygen and nitroxides. Invest Radiol 1987, 22:502-507. 10.1097/00004424-198706000-00011, 3040617.
63. Hahn SM, Krishna CM, Samuni A, DeGraff W, Cuscela DO, Johnstone P, Mitchell JB. Potential Use of Nitroxides in Radiation Oncology. Cancer Res 1994, 54:2006s-2010.
64. Muscoli C, Cuzzocrea S, Riley D, Zweier J, Thiemermann C, Wang Z, Salvemini D. On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies. Br J Pharmacol 2003, 140:445-460. 10.1038/sj.bjp.0705430, 1574047, 14522841.
65. Lejeune D, Hasanuzzaman M, Pitcock A, Francis J, Sehgal I. The superoxide scavenger TEMPOL induces urokinase receptor (uPAR) expression in human prostate cancer cells. Molecular Cancer 2006, 5:21. 10.1186/1476-4598-5-21, 1533855, 16756681.
66. Mitchell J, DeGraff W, Kaufman D, Krishna M, Samuni A, Finkelstein E, Ahn M, Hahn S, Gamson J, Russo A. Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic, tempol. Arch Biochem Biophys 1991, 289:62-70. 10.1016/0003-9861(91)90442-L, 1654848.
67. DeGraff W, Krishna M, Kaufman D, Mitchell J. Nitroxide-mediated protection against X-ray- and neocarzinostatin-induced DNA damage. Free Radic Biol Med 1992, 13:479-487. 10.1016/0891-5849(92)90142-4, 1459474.
68. DeGraff W, Krishna M, Russo A, Mitchell J. Antimutagenicity of a low molecular weight superoxide dismutase mimic against oxidative mutagens. Environ Mol Mutagen 1992, 19:21-26. 10.1002/em.2850190105, 1310080.
69. Augusto O, Trindade DF, Linares E, Vaz SM. Cyclic nitroxides inhibit the toxicity of nitric oxide-derived oxidants: mechanisms and implications. An Acad Bras Cienc 2008, 80:179-189.
70. Kennedy K, Teicher B, Rockwell S, Sartorelli A. The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem Pharmacol 1980, 29:1-8. 10.1016/0006-2952(80)90235-X, 6987986.
71. Hahn SM, Tochner Z, Krishna CM, Glass J, Wilson L, Samuni A, Sprague M, Venzon D, Glatstein E, Mitchell JB, Russo A. Tempol, a Stable Free Radical, Is a Novel Murine Radiation Protector. Cancer Res 1992, 52:1750-1753.
72. Dickey JS, Baird BJ, Redon CE, Sokolov MV, Sedelnikova OA, Bonner WM. Intercellular communication of cellular stress monitored by gamma-H2AX induction. Carcinogenesis 2009, 30:1686-1695. 10.1093/carcin/bgp192, 2757548, 19651821.
73. Martin RF, Broadhurst S, Reum ME, Squire CJ, Clark GR, Lobachevsky PN, White JM, Clark C, Sy D, Spotheim-Maurizot M, Kelly DP. In vitro studies with methylproamine: a potent new radioprotector. Cancer Res 2004, 64:1067-1070. 10.1158/0008-5472.CAN-03-2423, 14871839.
74. Pjura PE, Grzeskowiak K, Dickerson RE. Binding of Hoechst 33258 to the minor groove of B-DNA. J Mol Biol 1987, 197:257-271. 10.1016/0022-2836(87)90123-9, 2445998.
75. Sriram M, van der Marel GA, Roelen HL, van Boom JH, Wang AH. Conformation of B-DNA containing O6-ethyl-G-C base pairs stabilized by minor groove binding drugs: molecular structure of d(CGC[e6G]AATTCGCG complexed with Hoechst 33258 or Hoechst 33342. EMBO J 1992, 11:225-232. 556443, 1371249.
76. Lyubimova NV, Coultas PG, Yuen K, Martin RF. In vivo radioprotection of mouse brain endothelial cells by Hoechst 33342. Br J Radiol 2001, 74:77-82.
77. Martin RF, Anderson RF. Pulse radiolysis studies indicate that electron transfer is involved in radioprotection by Hoechst 33342 and methylproamine. Int J Radiat Oncol Biol Phys 1998, 42:827-831. 10.1016/S0360-3016(98)00316-2, 9845105.
78. Martin RF, Broadhurst S, D'Abrew S, Budd R, Sephton R, Reum M, Kelly DP. Radioprotection by DNA ligands. Br J Cancer Suppl 1996, 27:S99-101. 2149991, 8763857.
79. Denison L, Haigh A, D'Cunha G, Martin RF. DNA ligands as radioprotectors: molecular studies with Hoechst 33342 and Hoechst 33258. Int J Radiat Biol 1992, 61:561. 10.1080/09553009214550641, 1374112.
80. Martin RF, Denison L. DNA ligands as radiomodifiers: studies with minor-groove binding bibenzimidazoles. Int J Radiat Oncol Biol Phys 1992, 23:579-584. 10.1016/0360-3016(92)90014-9, 1377193.
81. Denison L, Haigh A, D'Cunha G, Martin RF. DNA ligands as radioprotectors: molecular studies with Hoechst 33342 and Hoechst 33258. Int J Radiat Biol 1992, 61:69-81. 10.1080/09553009214550641, 1370318.
82. Young SD, Hill RP. Radiation sensitivity of tumour cells stained in vitro or in vivo with the bisbenzimide fluorochrome Hoechst 33342. Br J Cancer 1989, 60:715-721. 10.1038/bjc.1989.346, 2247311, 2478182.
83. Lobachevsky PN, Vasireddy RS, Broadhurst S, Sprung CN, Karagiannis TC, Smith AJ, Radford IR, McKay MJ, Martin RF. Protection by methylproamine of irradiated human keratinocytes correlates with reduction of DNA damage. Int J Radiat Biol 2010,
84. Sprung CN, Vasireddy RS, Karagiannis TC, Loveridge SJ, Martin RF, McKay MJ. Methylproamine protects against ionizing radiation by preventing DNA double-strand breaks. Mutat Res 2010, 692:49-52.
85. Hortobágyi G. Anthracyclines in the treatment of cancer. An overview. Drugs 1997, 54(Suppl 4):1-7.
86. Gewirtz D. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999, 57:727-741. 10.1016/S0006-2952(98)00307-4, 10075079.
87. Chapman J. Single-hit mechanism of tumour cell killing by radiation. Int J Radiat Biol 2003, 79:71-81.
88. Weiss R. The anthracyclines: will we ever find a better doxorubicin?. Semin Oncol 1992, 19:670-686.
89. Zhang Y, Williams JR. Time-targeted therapy (TTT): Proof of principle using doxorubicin and radiation in a cultured cell system. Acta Oncol 2007, 46:621-627. 10.1080/02841860601009448, 17562438.
90. Kolarić K. Combination of cytostatics and radiation--a new trend in the treatment of inoperable esophageal cancer. Prog Clin Biol Res 1985, 201:259-82.
91. Banath JP, Olive PL. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res 2003, 63:4347-4350.
92. Karagiannis TC, Lin AJ, Ververis K, Chang L, Tang MM, Okabe J, El-Osta A. Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes. Aging (Albany NY) 2010, 2993796, 20930262.
93. Shin JS, Woo SH, Lee HC, Hong SW, Yoo DH, Hong SI, Lee WJ, Lee MS, Jin YW, An S, et al. Low doses of ionizing radiation suppress doxorubicin-induced senescence-like phenotypes by activation of ERK1/2 and suppression of p38 kinase in MCF7 human breast cancer cells. Int J Oncol 2010, 36:1445-1452.
94. Loser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA, Chalmers AJ. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther 2010, 9:1775-1787. 10.1158/1535-7163.MCT-09-1027, 2884153, 20530711.
95. Verheij M, Vens C, van Triest B. Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective. Drug Resist Updat 2010, 13:29-43. 10.1016/j.drup.2010.01.002, 20167530.
96. Hutchinson L. Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol 2010, 7:549. 10.1038/nrclinonc.2010.143, 20922827.
97. Chalmers AJ, Lakshman M, Chan N, Bristow RG. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol 2010, 20:274-281. 10.1016/j.semradonc.2010.06.001, 20832020.
98. Liang H, Tan AR. Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer. IDrugs 2010, 13:646-656.
99. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134. 10.1056/NEJMoa0900212, 19553641.
100. Carden CP, Yap TA, Kaye SB. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. Curr Opin Oncol 2010, 22:473-480. 10.1097/CCO.0b013e32833b5126, 20485165.
101. Zaremba T, Curtin NJ. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med Chem 2007, 7:515-523.
102. Mitchell C, Park M, Eulitt P, Yang C, Yacoub A, Dent P. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells. Mol Pharmacol 2010, 78:909-917. 10.1124/mol.110.067199, 20696794.
103. Beauchamp MC, Knafo A, Yasmeen A, Carboni JM, Gottardis MM, Pollak MN, Gotlieb WH. BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. Gynecol Oncol 2009, 115:193-198. 10.1016/j.ygyno.2009.07.009, 19699512.
104. Dong Y, Bey EA, Li LS, Kabbani W, Yan J, Xie XJ, Hsieh JT, Gao J, Boothman DA. Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation. Cancer Res 2010, 70:8088-8096. 10.1158/0008-5472.CAN-10-1418, 20940411.
105. Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, Kinders RJ, Parchment RE, Doroshow JH, Pommier Y. Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res 2010, 16:4532-4542. 10.1158/1078-0432.CCR-10-0523, 20823146.
106. Arundel C, Glicksman A, Leith J. Enhancement of radiation injury in human colon tumor cells by the maturational agent sodium butyrate (NaB). Radiat Res 1985, 104:443-448. 10.2307/3576603, 4080986.
107. Nackerdien Z, Michie J, Böhm L. Chromatin decondensed by acetylation shows an elevated radiation response. Radiat Res 1989 Feb;117(2):234-44 1989, 117:234-244.
108. Leith J. Effects of sodium butyrate and 3-aminobenzamide on survival of Chinese hamster HA-1 cells after X irradiation. Radiat Res 1988, 114:186-191. 10.2307/3577154, 3353504.
109. Marks P, Xu W. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009, 107:600-608. 10.1002/jcb.22185, 2766855, 19459166.
110. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401:188-193. 10.1038/43710, 10490031.
111. Kelly WK, O'Connor OA, Marks PA. Histone deacetylase inhibitors: from target to clinical trials. Expert Opinion on Investigational Drugs 2002, 11:1695-1713. 10.1517/13543784.11.12.1695, 12457432.
112. Spotswood HT, Turner BM. An increasingly complex code. The Journal of Clinical Investigation 2002, 110:577-582. 151116, 12208855.
113. Lin HY, Chen CS, Lin SP, Weng JR, Chen CS. Targeting histone deacetylase in cancer therapy. Med Res Rev 2006, 26:397-413. 10.1002/med.20056, 16450343.
114. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation?. EMBO J 2000, 19:1176-1179. 10.1093/emboj/19.6.1176, 305658, 10716917.
115. Di Gennaro E, Bruzzese F, Caraglia M, Abruzzese A, Budillon A. Acetylation of proteins as novel target for antitumor therapy: review article. Amino Acids 2004, 26:435-441. 10.1007/s00726-004-0087-3, 15290351.
116. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26:5541-5552. 10.1038/sj.onc.1210620, 17694093.
117. Zhang Y, Carr T, Dimtchev A, Zaer N, Dritschilo A, Jung M. Attenuated DNA damage repair by trichostatin A through BRCA1 suppression. Radiat Res 2007, 168:115-124. 10.1667/RR0811.1, 17722998.
118. Palmieri D, Lockman PR, Thomas FC, Hua E, Herring J, Hargrave E, Johnson M, Flores N, Qian Y, Vega-Valle E, et al. Vorinostat Inhibits Brain Metastatic Colonization in a Model of Triple-Negative Breast Cancer and Induces DNA Double-Strand Breaks. Clin Cancer Res 2009, 15:6148-6157. 10.1158/1078-0432.CCR-09-1039, 19789319.
119. Zgheib O, Huyen Y, DiTullio RJ, Snyder A, Venere M, Stavridi E, Halazonetis T. ATM signaling and 53BP1. Radiother Oncol 2005 Aug;76(2):119-22 2005, 76:119-122.
120. Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM. Modulation of radiation response by histone deacetylase inhibition. International Journal of Radiation Oncology*Biology*Physics 2005, 62:223-229.
121. Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL, Ismail S, Stevens C, Meyn RE. Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing DNA Repair Activity. Clin Cancer Res 2005, 11:4912-4922. 10.1158/1078-0432.CCR-04-2088, 16000590.
122. Downs JA, Nussenzweig MC, Nussenzweig A. Chromatin dynamics and the preservation of genetic information. Nature 2007, 447:951-958. 10.1038/nature05980, 17581578.
123. Karagiannis TC, Harikrishnan KN, El-Osta A. The histone deacetylase inhibitor, Trichostatin A, enhances radiation sensitivity and accumulation of gamma H2A.X. Cancer Biology & Therapy 2005, 4:787-793.
124. Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE. Histone Deacetylase (HDAC) Inhibitor LBH589 Increases Duration of {gamma}-H2AX Foci and Confines HDAC4 to the Cytoplasm in Irradiated Non-Small Cell Lung Cancer. Cancer Res 2006, 66:11298-11304. 10.1158/0008-5472.CAN-06-0049, 17145876.
125. Chung YL, Lee MY, Pui NNM. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis. Carcinogenesis 2009, 30:1387-1397. 10.1093/carcin/bgp079, 19351790.
126. Harikrishnan KN, Karagiannis TC, Chow MZ, El-Osta A. Effect of valproic acid on radiation-induced DNA damage in euchromatic and heterochromatic compartments. Cell Cycle 2008, 7:468-476. 10.4161/cc.7.4.5405, 18239454.
127. Zhang F, Zhang T, Teng Z, Zhang R, Wang J, Mei Q. Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells. Cancer Biol Ther 2009, 8:823-831. 10.1158/1535-7163.MCT-08-0544, 19270532.
128. Kim J, Shin J, Kim I. Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys 2004, 59:1174-1180. 10.1016/j.ijrobp.2004.03.001, 15234053.
129. Chinnaiyan P, Cerna D, Burgan WE, Beam K, Williams ES, Camphausen K, Tofilon PJ. Postradiation Sensitization of the Histone Deacetylase Inhibitor Valproic Acid. Clin Cancer Res 2008, 14:5410-5415. 10.1158/1078-0432.CCR-08-0643, 18765532.
130. Camphausen K, Cerna D, Scott T, Sproull M, Burgan W, Cerra M, Fine H, Tofilon P. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 2005, 114:380-386. 10.1002/ijc.20774, 15578701.
131. Baschnagel A, Russo A, Burgan WE, Carter D, Beam K, Palmieri D, Steeg PS, Tofilon P, Camphausen K. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther 2009, 8:1589-1595. 10.1158/1535-7163.MCT-09-0038, 19509253.
132. De Schutter H, Kimpe M, Isebaert S, Nuyts S. A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2009, 73:904-912. 10.1016/j.ijrobp.2008.10.032, 19215824.
133. Kelly W, Marks P. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005, 2:150-157. 10.1038/ncponc0106, 16264908.
134. Karagiannis TC, Harikrishnan KN, El-Osta A. Disparity of histone deacetylase inhibition on repair of radiation-induced DNA damage on euchromatin and constitutive heterochromatin compartments. Oncogene 2007, 26:3963-3971. 10.1038/sj.onc.1210174, 17213813.
135. Belli JA, Hellman S. Editorial: Hypoxic cell radiosensitizers. N Engl J Med 1976, 294:1399-1400. 10.1056/NEJM197606172942511, 177876.
136. Phillips TL, Wasserman TH, Johnson R, Gomer CJ, Lawrence GA, Levine ML, Sadee W, Penta JS, Rubin DJ. The hypoxic cell sensitizer programme in the United States. Br J Cancer Suppl 1978, 3:276-280. 2149383, 277245.
137. Bischoff P, Altmeyer A, Dumont F. Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers. Expert Opin Ther Pat 2009, 19:643-662. 10.1517/13543770902824172, 19441939.
138. Olive PL, Banath JP, Sinnott LT. Phosphorylated histone H2AX in spheroids, tumors, and tissues of mice exposed to etoposide and 3-amino-1,2,4-benzotriazine-1,3-dioxide. Cancer Res 2004, 64:5363-5369. 10.1158/0008-5472.CAN-04-0729, 15289343.
139. Wardman P, Rothkamm K, Folkes LK, Woodcock M, Johnston PJ. Radiosensitization by nitric oxide at low radiation doses. Radiat Res 2007, 167:475-484. 10.1667/RR0827.1, 17388699.
140. Palayoor ST, Mitchell JB, Cerna D, Degraff W, John-Aryankalayil M, Coleman CN. PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer 2008, 123:2430-2437. 10.1002/ijc.23807, 18729192.
141. Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res 2007, 13:3922-3932. 10.1158/1078-0432.CCR-07-0478, 17606726.
142. Evans JW, Chernikova SB, Kachnic LA, Banath JP, Sordet O, Delahoussaye YM, Treszezamsky A, Chon BH, Feng Z, Gu Y, et al. Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. Cancer Res 2008, 68:257-265. 10.1158/0008-5472.CAN-06-4497, 18172318.
143. Economopoulou M, Langer HF, Celeste A, Orlova VV, Choi EY, Ma M, Vassilopoulos A, Callen E, Deng C, Bassing CH, et al. Histone H2AX is integral to hypoxia-driven neovascularization. Nat Med 2009, 15:553-558. 10.1038/nm.1947, 2713773, 19377486.
144. van den Aardweg G, Hopewell J. The kinetics of repair for sublethal radiation-induced damage in the pig epidermis: an interpretation based on a fast and a slow component of repair. Radiother Oncol 1992, 23:94-104. 10.1016/0167-8140(92)90340-Z, 1546193.
145. Hume S, Myers R. An unexpected effect of hyperthermia on the expression of X-ray damage in mouse skin. Radiat Res 1984, 97:186-199. 10.2307/3576200, 6695042.
146. Withers HR, Kathryn AM. The kinetics of recovery in irradiated colonic mucosa of the mouse. Cancer 1974, 34:896-903. 10.1002/1097-0142(197409)34:3+<896::AID-CNCR2820340717>3.0.CO;2-P, 4854926.
147. Haagen J, Krohn H, Röllig S, Schmidt M, Wolfram K, Dörr W. Effect of selective inhibitors of inflammation on oral mucositis: Preclinical studies. Radiother Oncol 2009, 92:472-476. 10.1016/j.radonc.2009.06.006, 19576646.
148. Dörr W, Kummermehr J. Accelerated repopulation of mouse tongue epithelium during fractionated irradiations or following single doses. Radiother Oncol 1990, 17:249-259.
149. Dorr W, Heider K, Spekl K. Reduction of oral mucositis by palifermin (rHuKGF): Dose-effect of rHuKGF. Int J Radiat Biol 2005, 81:557-565. 10.1080/09553000500196136, 16298937.
150. Gonzalez JE, Roch-Lefevre SH, Mandina T, Garcia O, Roy L. Induction of gamma-H2AX foci in human exfoliated buccal cells after in vitro exposure to ionising radiation. Int J Radiat Biol 2010, 86:752-759. 10.3109/09553002.2010.484476, 20597838.
151. Bhogal N, Kaspler P, Jalali F, Hyrien O, Chen R, Hill RP, Bristow RG. Late residual gamma-H2AX foci in murine skin are dose responsive and predict radiosensitivity in vivo. Radiat Res 2010, 173:1-9. 10.1667/RR1851.1, 20041754.
152. Qvarnstrom OF, Simonsson M, Johansson KA, Nyman J, Turesson I. DNA double strand break quantification in skin biopsies. Radiother Oncol 2004, 72:311-317. 10.1016/j.radonc.2004.07.009, 15450730.
153. Qvarnström O, Simonsson M, Johansson K, Nyman J, Turesson I. DNA double strand break quantification in skin biopsies. Radiother Oncol 2004 Sep;72(3):311-7 2004, 72:311-317.
154. Sak A, Grehl S, Erichsen P, Engelhard M, Grannaß A, LevegrÃ1-Aprn S, Pöttgen C, Groneberg M, Stuschke M. gamma-H2AX foci formation in peripheral blood lymphocytes of tumor patients after local radiotherapy to different sites of the body: Dependence on the dose-distribution, irradiated site and time from start of treatment. Int J Radiat Biol 2007, 83:639-652. 10.1080/09553000701596118, 17729159.
155. Pogrlbny I, Koturbash I, Tryndyak V, Hudson D, Stevenson SML, Sedelnikova O, Bonner W, Kovalchuk O. Fractionated low-dose radiation exposure leads to accumulation of DNA damage and profound alterations in DNA and histone methylation in the murine thymus. Mol Cancer Res 2005, 3:553-561. 10.1158/1541-7786.MCR-05-0074, 16254189.
156. Rothkamm K, Horn S. gamma-H2AX as protein biomarker for radiation exposure. Ann Ist Super Sanita 2009, 45:265-271.
157. Jones T, Kang I, Wheeler D, Lindquist R, Papallo A, Sabatini D, Golland P, Carpenter A. CellProfiler Analyst: data exploration and analysis software for complex image-based screens. BMC Bioinformatics 2008, 9:482. 10.1186/1471-2105-9-482, 2614436, 19014601.
158. Böcker W, Iliakis G. Computational Methods for analysis of foci: validation for radiation-induced gamma-H2AX foci in human cells. Radiat Res 2006, 165:113-124.
159. Hou YN, Lavaf A, Huang D, Peters S, Huq R, Friedrich V, Rosenstein BS, Kao J. Development of an Automated gamma-H2AX Immunocytochemistry Assay. Radiat Res 2009, 171:360-367. 10.1667/RR1349.1, 19267563.
160. Garty G, Chen Y, Salerno A, Turner H, Zhang J, Lyulko O, Bertucci A, Xu Y, Wang H, Simaan N, et al. The RABIT: a rapid automated biodosimetry tool for radiological triage. Health Phys 2010, 98:209-217. 10.1097/HP.0b013e3181ab3cb6, 20065685.
161. Lobrich M, Rief N, Kuhne M, Heckmann M, Fleckenstein J, Rube C, Uder M. In vivo formation and repair of DNA double-strand breaks after computed tomography examinations. Proc Natl Acad Sci USA 2005, 102:8984-8989. 10.1073/pnas.0501895102, 1150277, 15956203.
162. Rothkamm K, Balroop S, Shekhdar J, Fernie P, Goh V. Leukocyte DNA Damage after Multi†"Detector Row CT: A Quantitative Biomarker of Low-Level Radiation Exposure1. Radiology 2007, 242:244-251. 10.1148/radiol.2421060171, 17185671.